Abstract: The present invention relates to novel retinoid-related orphan receptor gamma (ROR?) modulators and their use in the treatment of diseases mediated by ROR?.

Abstract: A process for producing a diazabicyclooctane derivative represented by Formula (IV) and intermediates thereof by carrying out the following steps: wherein P is an NH protecting group capable of being removed with acid; R1 is 2,5-dioxopyrrolidin-1-yl, 1,3-dioxo-3a,4,7,7a-tetrahydro-1H-isoindol-2(3H)-yl, 1,3-dioxohexahydro-1H-isoindol-2(3H)-yl, or 3,5-dioxo-4-azatricyclo[5.2.1.02.6]dec-8-en-4-yl; R2 is hydrogen, ClCO— or Cl3COCO—; R3 is C1-6 alkyl or heterocyclyl, or forms a 3- to 7-membered heterocyclic ring together with the —O—NH— to which it is attached; and OBn is benzyloxy.

Abstract: An acid composition comprising 2-formyl-furan-5-carboxylic acid and 2,5-furandicarboxylic acid is purified in a process which comprises; contacting the acid composition with an alcohol to obtain an esterified composition; and separating the ester of 2-formyl-furan-5-carboxylic acid from the esterified composition to obtain a purified esterified product; and contacting the purified esterified composition with water for saponification or hydrolysis, to obtain a product composition, comprising 2,5-furandicarboxylic acid and a reduced amount of 2-formyl-furan-5-carboxylic acid.

Abstract: A method for extracting cannabinoids from plant material containing one or more cannabinoids including: (1) shredding the plant material into an appropriate size; (2) soaking the shredded plant material in a polar solvent to dissolve the one or more cannabinoids into the alcohol to form a polar solvent/cannabinoid mixture; (3) separating the polar solvent/cannabinoid mixture from residual solid plant material; (4) treating the polar solvent/cannabinoid mixture to a non-polar solvent to remove the one or more cannabinoids into the non-polar solvent to form a non-polar solvent/cannabinoid mixture; (5) distilling the non-polar solvent/cannabinoid mixture to separate the non-polar solvent from the one or more cannabinoids; and (6) subjecting the cannabinoid mixture to a supercritical fluid to isolate and purify the cannabinoid mixture into individual cannabinoids of the one or more cannabinoids.

Abstract: The invention relates to novel 3,5-dichloro,4-(3,4-(cyclo-) alkoxyphenyl)-2-carbonyloxy)ethyl)pyridine compounds which are both inhibitors of the phosphodiesterase 4 (PDE4) enzyme and muscarinic M3 receptor antagonists, methods of preparing such compounds, compositions containing them and therapeutic use thereof.

Abstract: Provided are an injection preparation which include: an aqueous composition containing pemetrexed or a salt thereof, at least one antioxidant agent which is selected from the group consisting of ascorbic acid, an ascorbic acid derivative, and salts thereof, and the content of which is 0.0001 mass % to 0.5 mass % with respect to the total mass of the aqueous composition in terms of ascorbic acid, and an aqueous solvent of greater than or equal to 50 mass % with respect to the total mass of the aqueous composition; and a container which encloses the aqueous composition, in which the concentration of oxygen in gas within the container which encloses the aqueous composition is less than or equal to 0.2 volume %, and a method for producing the injection preparation.

Abstract: The present invention relates to a catalyst system for oxidation of o-xylene and/or naphthalene to phthalic anhydride (PA), comprising a plurality of catalyst zones arranged in succession in the reaction tube, which have been produced using antimony trioxide comprising a noticeable proportion of senarmontite wherein some of the primary crystallites have a size of less than 200 nm. The present invention further relates to a process for gas phase oxidation, in which a gas stream comprising at least one hydrocarbon and molecular oxygen is passed through a catalyst system which comprises a plurality of catalyst zones arranged in succession in the reaction tube and which has been produced using an antimony trioxide comprising a noticeable proportion of senarmontite wherein some of the primary crystallites have a size of less than 200 nm.

Abstract: This present disclosure is related to the field of N1-sulfonyl-5-fluoropyrimidinones and their derivatives and to the use of these compounds as fungicides.

Abstract: This disclosure is related to methods for producing anhydroryanodol, ryanodol, or analogs thereof and novel compounds prepared thereby.

Abstract: A method for obtaining polyphenols from a vegetable raw material containing same, includes at least the following steps: optionally drying the raw material containing the polyphenols; crushing the raw material; defibrating the crushed raw material in an extruder in the presence of a solvent; separating the soluble phase from the fibers; and recovering the soluble phase, crude extract, containing the polyphenols.

Abstract: Provided is a method for producing a cyclic carbonate obtained by reacting epoxide and carbon dioxide in the presence of a quaternary onium salt as a counter ion or a quaternary phosphonium salt having a halogenated anion as a counter ion, or in the presence of a solid catalyst obtained by immobilizing the quaternary onium salt onto a carrier, wherein an organohalogen compound containing at least one halogen atom in one molecule is added to the reaction system.

Abstract: The present disclosure is directed to methods for reducing cardiovascular risk in a human subject by administering atrasentan, or a pharmaceutically acceptable salt thereof, in an amount sufficient to effect a reduction of about 5% or more in one or both of (a) total serum cholesterol, relative to the subject's baseline total serum cholesterol, and (b) serum LDL cholesterol, relative to the subject's baseline serum LDL cholesterol.

Abstract: Dapagliflozin compounds and process for dapagliflozin preparation are described. Pharmaceutical compositions comprising dapagliflozin or solvates of dapagliflozin, for the treatment of diabetes are also described.

Abstract: The invention generally relates to methods of treating a patient suffering from hypothalamic obesity using effective of amounts of a MetAP-2 inhibitor.

Abstract: The present disclosure relates to carbon monoxide releasing molecules (“CORMs”), and methods of synthesizing and applying the molecules. More specifically, this disclosure relates to structurally tunable CORMS, compounds containing CORMS (and salts thereof).

Abstract: A method for extracting the compound 3-methyl-2H-furo[2,3-c]pyran-2-one from smoke, the method comprising pyrolysis of cellulose or any biomass within a combustion chamber, directing the smoke into a scrubbing apparatus incorporating a spiral condenser tube extending along the chamber and having a number of mist spray units spaced along the entire spiral condenser tube, collecting smoke water thus formed and passing it to a cooling chamber and then to preparation for storage or despatch.

Abstract: Modulators of intracellular chloride concentration for treating down syndrome The present invention relates to a modulator of a chloride transporter for use in the treatment of Down syndrome.

Abstract: The invention relates to polymorphous crystal modifications of a DPP-IV inhibitor, the preparation thereof and the use thereof for preparing a medicament.

Abstract: The present invention provides a low-toxic and high-recovery industrial process for synthesizing an optically active diamine derivative represented by formula (D), the process comprising the steps of: (a) mixing a compound represented by formula (A) and a compound represented by formula (C) in organic solvents and secondary amine; (b) reaction under heating; (c) cooling and adding water to the mixed solution, allowing it to crystallize to obtain the compound represented by formula (D).

Abstract: The present invention relates to a novel process for producing of 2,3-dichloro-5-(trichloromethyl)pyridine by using PCl as chlorinating agent at elevated temperature and pressure.